“Results of a phase 3 trial in the New England Journal of Medicine show 80% protection for the single-dose tetravalent (four-strain) Butantan-Dengue Vaccine among participants with no evidence of previous dengue exposure and 89% protection in those with a history of exposure.

The vaccine is the culmination of years of research from Brazil’s Butantan Institute, and the study included results from 16 Brazilian centers located in all five regions of the country.”